We are live on
!
Find out more
EAM
Eventide Asset Management Portfolio holdings
AUM
$6.05B
1-Year Est. Return
76.64%
This Fund
S&P 500
This Quarter
Est. Return
+13.36%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$1.76B
AUM Growth
+$158M
(+9.9%)
Cap. Flow
+$12.9M
Cap. Flow
% of AUM
0.73%
Top 10 Holdings %
Top 10 Hldgs %
26.37%
Holding
139
New
12
Increased
27
Reduced
23
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ELLI
Ellie Mae Inc
ELLI
|
+$22.2M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$21.9M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$16.2M |
| 4 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$13.2M |
| 5 |
FIVE9
FIVN
|
+$12.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$19M |
| 2 |
BLUE
bluebird bio
BLUE
|
+$17M |
| 3 |
SPLK
Splunk Inc
SPLK
|
+$10.6M |
| 4 |
PFPT
Proofpoint, Inc.
PFPT
|
+$9.51M |
| 5 |
KITE
Kite Pharma, Inc.
KITE
|
+$8.81M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.21% |
| 2 | Technology | 13.87% |
| 3 | Consumer Discretionary | 13.68% |
| 4 | Industrials | 7.76% |
| 5 | Utilities | 4.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TERP
126
DELISTED
TerraForm Power, Inc
TERP
| $694K | 0.04% |
52,500
+9,500
| +22% | +$124K |
|
|
CCI.PRA
127
DELISTED
Crown Castle International Corp. 6.875% Mandatory Convertible Preferred Stock, Series A
CCI.PRA
| $641K | 0.04% |
+600
| New | +$649K |
|
128
Ericsson
ERIC
$32.1B
| $604K | 0.03% |
105,000
+15,000
| +17% | +$92.7K |
|
129
LXP Industrial Trust
LXP
$3.58B
| $562K | 0.03% |
11,000
+1,000
| +10% | +$50K |
|
|
LPT
130
DELISTED
Liberty Property Trust
LPT
| $493K | 0.03% |
12,000
| – | – |
|
131
Ventas
VTR
$47.1B
| $456K | 0.03% |
7,000
| – | – |
|
132
Welltower
WELL
$170B
| $387K | 0.02% |
5,500
| – | – |
|
133
Acuity Brands
AYI
$10.1B
| $343K | 0.02% |
2,000
| – | – |
|
|
VIRX
134
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $25K | ﹤0.01% |
+374
| New | +$30.5K |
|
135
CytomX Therapeutics
CTMX
$714M
| – | – |
-150,000
| Closed | -$2.33M |
|
136
Hercules Capital
HTGC
$2.98B
| – | – |
-100,000
| Closed | -$1.32M |
|
|
KITE
137
DELISTED
Kite Pharma, Inc.
KITE
| – | – |
-85,000
| Closed | -$8.81M |
|
Similar funds
HPG
EMPI
RCG
JWBC
AAM
AA
CM
CIS
Eventide Asset Management's Q3 2017 Portfolio in Review
As of Q3 2017, Eventide Asset Management held 139 positions worth $1.76B, up 9.9% from $1.61B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Eventide Asset Management's Q3 2017 filing shows 12 new, 27 increased, 23 reduced and 3 closed positions. Its largest new stake was Ellie Mae Inc: 242,000 shares worth $19.9M. The largest sale was Loxo Oncology, Inc, an estimated $19M.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 35% a quarter earlier, followed by Technology and Consumer Discretionary.
- Eventide Asset Management's largest Q3 2017 buy was Ellie Mae Inc: 242,000 shares worth $19.9M.
- Eventide Asset Management added most to Vertex Pharmaceuticals in Q3 2017, an estimated $21.9M increase.
- Eventide Asset Management's biggest Q3 2017 reduction was Loxo Oncology, Inc, cutting an estimated $19M.
- Eventide Asset Management fully exited Kite Pharma, Inc. in Q3 2017, selling an estimated $8.81M.
- Eventide Asset Management's ten largest holdings make up 26% of its $1.76B portfolio in Q3 2017.
- Eventide Asset Management opened 12 new positions and closed 3 in Q3 2017.
- Eventide Asset Management's portfolio value rose 9.9% quarter-over-quarter to $1.76B.
Based on Eventide Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.